Table 4.
Possible Changes in the CDLB Criteria with Results from Prospective Cases
| Alzheimer-type pathology | |||||
|---|---|---|---|---|---|
| NIA Low (Braak stage 0-II) | NIA Interm. (Braak stage III-IV) | NIA High (Braak stage V | NIA High (Braak stage VI) | ||
| Lewy body pathology | No Lewy bodies | CDLB Low 0/3*** | CDLB Low 0/9 | CDLB Low 0/3 | CDLB Low 1*/7 |
| Amygdala only | CDLB Low 0 | CDLB Low 0 | CDLB Low 0 | CDLB Low 0/2 | |
| Brainstem | CDLB Low 0 | CDLB Low 0 | CDLB Low 0 | CDLB Low 0 | |
| Limbic | CDLB High 2/2 | CDLB Interm 2/2 | CDLB Low 0/1 | CDLB Low 2/4 | |
| Diffuse | CDLB High 6/6 | CDLB High 20/21 | CDLB Interm. 9/10 | CDLB Low 1/5 | |
Possible changes in the CDLB criteria with results from prospective cases. Each box shows the ratio of clinically probable DLB to the total number of cases in that pathologic category for all 76 prospectively diagnosed DLB and AD cases.
*
Includes 1 mixed PSP/AD case that had clinically probable DLB.
**
Includes 2 cases of FTLD-U and 1 case of CBD with clinically probable AD.